These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22184053)

  • 21. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.
    Zhang X; Wojtkowiak JW; Martinez GV; Cornnell HH; Hart CP; Baker AF; Gillies R
    PLoS One; 2016; 11(5):e0155289. PubMed ID: 27227903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
    Liu Q; Sun JD; Wang J; Ahluwalia D; Baker AF; Cranmer LD; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1487-98. PubMed ID: 22382881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
    Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.
    Yamazaki H; Lai YC; Tateno M; Setoguchi A; Goto-Koshino Y; Endo Y; Nakaichi M; Tsujimoto H; Miura N
    PLoS One; 2017; 12(5):e0177305. PubMed ID: 28489881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
    Wang B; Qi FZ; Chen P; Qian LM; Su HS; Wang Y; Wang CH; Hou YX; Zhang Q; Li D; Chen ZS; Zhang SH
    Int J Biol Sci; 2024; 20(5):1634-1651. PubMed ID: 38481819
    [No Abstract]   [Full Text] [Related]  

  • 28. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
    Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
    Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Hu J; Handisides DR; Van Valckenborgh E; De Raeve H; Menu E; Vande Broek I; Liu Q; Sun JD; Van Camp B; Hart CP; Vanderkerken K
    Blood; 2010 Sep; 116(9):1524-7. PubMed ID: 20530289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    Jamieson SM; Tsai P; Kondratyev MK; Budhani P; Liu A; Senzer NN; Chiorean EG; Jalal SI; Nemunaitis JJ; Kee D; Shome A; Wong WW; Li D; Poonawala-Lohani N; Kakadia PM; Knowlton NS; Lynch CR; Hong CR; Lee TW; Grénman RA; Caporiccio L; McKee TD; Zaidi M; Butt S; Macann AM; McIvor NP; Chaplin JM; Hicks KO; Bohlander SK; Wouters BG; Hart CP; Print CG; Wilson WR; Curran MA; Hunter FW
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
    Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
    [No Abstract]   [Full Text] [Related]  

  • 34. Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.
    Cárdenas-Rodríguez J; Li Y; Galons JP; Cornnell H; Gillies RJ; Pagel MD; Baker AF
    Magn Reson Imaging; 2012 Sep; 30(7):1002-9. PubMed ID: 22554971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
    Pourmorteza M; Rahman ZU; Young M
    Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
    Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
    Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondria-targeting multifunctional nanoplatform for cascade phototherapy and hypoxia-activated chemotherapy.
    Lv J; Wang S; Qiao D; Lin Y; Hu S; Li M
    J Nanobiotechnology; 2022 Jan; 20(1):42. PubMed ID: 35062959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.